Organon & Co. (OGN): Capital Expenditures
$162.00M
Year ended 2025-12-31
$170.00M
Trailing 12 months to 2026-06-30
-6.2%
3-year compound annual growth
-8.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $162.00M | -7.4% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $175.00M | -30.3% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $251.00M | +28.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $196.00M | +2.1% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $192.00M | -24.7% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $255.00M | +177.2% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $92.00M | n/a | 2022-03-21, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $162.00M | -7.4% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $185.84M | -62.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $276.00M | +87.8% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $58.75M | +54.3% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $93.40M | -21.0% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $621.00M | -5.2% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $397.00M | +17.8% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $58.70M | +71.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $103.04M | +20.6% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗